The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recognized with official accreditation for CAR T-cell therapy from the Foundation for the Accreditation of Cellular Therapy, an international accrediting body. The program was also ranked among the top adult bone marrow transplant programs in the U.S. for a third year.
Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.
